Showing results (851-860 of 919) with videos related to

Sort By:
Pageof 92
Annals of Surgical Oncology|August 28, 2025
Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic CancerYuto Kamioka, Yukihiko Hiroshima, Wataru Kawase, et al.
Acta Cytologica|December 6, 2021
Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign LesionsAkihiko Yoshizawa, Kenzo Hiroshima, Akemi Takenaka, et al.
Acta Cytologica|March 31, 2020
Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology SpecimensKenzo Hiroshima, Akihiko Yoshizawa, Akemi Takenaka, et al.
Clinical Colorectal Cancer|January 19, 2016
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study)Tomohiro Nishina, Toshikazu Moriwaki, Mitsuo Shimada, et al.
Oncotarget|February 10, 2016
Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) modelTakashi Murakami, Jonathan DeLong, Fritz C Eilber, et al.
World Journal of Surgical Oncology|October 1, 2025
Safety and pathological impact of resection after high-dose PBT for locally advanced pancreatic cancerOsamu Shimomura, Haruko Numajiri, Shinji Hashimoto, et al.
Plos One|June 6, 2015
Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse ModelsYukihiko Hiroshima, Yong Zhang, Ming Zhao, et al.
Oncotarget|August 11, 2020
Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trialTakashi Oshima, Takaki Yoshikawa, Yohei Miyagi, et al.
Anticancer Research|April 4, 2021
Clinical Significance of Stanniocalcin2 mRNA Expression in Patients With Colorectal CancerTakuo Watanabe, Manabu Shiozawa, Yayoi Kimura, et al.
Cell Cycle (Georgetown, Tex.)|January 16, 2018
Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse modelKentaro Miyake, Kei Kawaguchi, Tasuku Kiyuna, et al.
Pageof 92